NeuropaceNPCE
Market Cap: 229M
About: NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
Employees: 181
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
285% more call options, than puts
Call options by funds: $381K | Put options by funds: $99K
260% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 5
200% more funds holding in top 10
Funds holding in top 10: 0 [Q4 2023] → 2 (+2) [Q1 2024]
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
32% more funds holding
Funds holding: 41 [Q4 2023] → 54 (+13) [Q1 2024]
23% more capital invested
Capital invested by funds: $143M [Q4 2023] → $176M (+$33.5M) [Q1 2024]
5.61% less ownership
Funds ownership: 52.75% [Q4 2023] → 47.15% (-5.61%) [Q1 2024]
Research analyst outlook
8 Wall Street Analysts provided 1 year price forecasts over the past 6 months
8 analyst ratings
Morgan Stanley Drew Ranieri | 1%upside $8 | Equal-Weight Maintained | 15 Jul 2024 |
Cantor Fitzgerald Ross Osborn | 126%upside $18 | Overweight Reiterated | 9 May 2024 |
Wells Fargo Lawrence Biegelsen | 151%upside $20 | Overweight Upgraded | 14 Mar 2024 |
JP Morgan Robbie Marcus | 114%upside $17 | Overweight Maintained | 12 Mar 2024 |
Cantor Fitzgerald Ross Osborn | 126%upside $18 | Overweight Maintained | 6 Mar 2024 |